Skip to main content
Blood Advances logoLink to Blood Advances
. 2020 Jan 7;4(1):112. doi: 10.1182/bloodadvances.2019001362

Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

PMCID: PMC6960462  PMID: 31910259

The generic names of some drugs were omitted from the original supplemental data. The error has been corrected in the online data supplement.


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES